The first clinical trial of olaparib (NCT00516373) included three patients with advanced prostate cancer, including one patient with a BRCA2 mutation who had a greater than 50% reduction in PSA level and resolution of bone metastases [41]. This evidence concerns the gene BRCA2 and prostate carcinoma.